Hologic Inc. closed 22.70% short of its 52-week high of $84.67, which the company reached on August 9th.

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Madison Keys, who captured her first Grand Slam title last month in Melbourne, has not played since her title-run Down Under.

Raymond James lowered the firm’s price target on Hologic (HOLX) to $90 from $95 and keeps an Outperform rating on the shares. Hologic’s print ...

Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Explore advancements in women's health through AI, equity, and policy with Mia Keeys of Hologic on I Don’t Care.

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...